Currently, the medical studies are clear that the use of appetite suppressants such as Pondimin, Redux, fenfluramine or dexfenfluramine greatly increase one's chances of developing primary pulmonary hypertension (PPH). An association between the anorexigen aminorex and PH was first reported in the 1960s, and aminorex was withdrawn from the market in 1972. In the 1980s, fenfluramine use was linked to Primary Pulmonary Hypertension, PPH, and/or primary PH and, subsequently, a 30-fold increase in the risk of PH was found in patients who had received these appetite suppressants for longer than 3 months compared with the general population. While the research is not totally complete, we believe that research will find a direct connection to link Phenylpropanolamine (PPA) with increased risks of primary pulmonary hypertension (PPH). Patients that have been diagnosed with PPH and were not prescribed Fen Phen, Redux or Pondimin may consider that other anorexigens, such as ephedra, ephedrine or Phenylpropanolamine PPA  may be the underlying culprit in their diagnosis.

It is our belief that the underlying cause of PPH for many patients has been a complete mystery and as the science continues to make advances, we believe that we will be able to show the direct connection between ephedra, phenylpropanolamine PPA, and ephedrine containing diet supplements, cold medicines and appetite suppressing drugs and PPH. If you have been diagnosed with Primary Pulmonary Hypertension (PPH) and have used products with ephedra, ephedrine or phenylpropanolamine, then call us to discuss.  No Attorneys Fees or Expenses Charged Unless we make a Recovery for you. The Willis Firm is currently representing a several ephedra related PPH cases and are currently representing a PPH patient that consumed only Dexatrim and an ephedra containing diet / herbal supplement. For a Free Consultation call us at 1-800-883-9858.

        Call Us Toll Free at 1-800-883-9858 or 1-800-468-4878 or E-mail us your questions on Free Case Evaluation Form.